Equity
Additional Paid-In Capital
Vertex Pharmaceuticals Additional Paid-In Capital decreased by 7.3% to $4.74B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 23.2%, from $6.17B to $4.74B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows a downward trend with a -8.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates equity financing or the issuance of shares for employee compensation, signaling capital raising or dilution.
Detailed definition
This represents the excess amount paid by shareholders for common stock over its par value. It is a primary component of...
Peer comparison
Standard equity account for all publicly traded companies.
Metric ID:
equity_additional_paid_in_capital_common_stockHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.64B | $7.09B | $6.88B | $6.93B | $7.10B | $7.23B | $7.39B | $7.22B | $7.37B | $7.34B | $7.45B | $7.28B | $7.10B | $6.91B | $6.67B | $6.17B | $5.99B | $5.01B | $5.12B | $4.74B |
| QoQ Change | — | -7.3% | -2.9% | +0.7% | +2.5% | +1.8% | +2.2% | -2.3% | +2.1% | -0.4% | +1.5% | -2.2% | -2.5% | -2.8% | -3.4% | -7.5% | -3.0% | -16.3% | +2.1% | -7.3% |
| YoY Change | — | — | — | — | -7.1% | +2.0% | +7.3% | +4.2% | +3.8% | +1.6% | +0.9% | +0.9% | -3.6% | -5.9% | -10.4% | -15.3% | -15.7% | -27.4% | -23.3% | -23.2% |
Range$4.74B – $7.64B
CAGR-9.5%
Avg YoY Growth-7.0%
Median YoY Growth-4.8%
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's additional paid-in capital?
- Vertex Pharmaceuticals (VRTX) reported additional paid-in capital of $4.74B in Q1 2026.
- How has Vertex Pharmaceuticals's additional paid-in capital changed year-over-year?
- Vertex Pharmaceuticals's additional paid-in capital decreased by 23.2% year-over-year, from $6.17B to $4.74B.
- What is the long-term trend for Vertex Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's additional paid-in capital has grown at a -8.3% compound annual growth rate (CAGR), from $7.89B to $5.12B.
- What does additional paid-in capital mean?
- The total amount of money investors paid for shares above the nominal par value.